International Journal of Hematologic Oncology Archives

Must read

15 May 2018 Hematologic
Management of older adults with acute lymphoblastic leukemia: challenges & current approaches

6 Sep 2017 Hematologic
In Focus: Blood cancer
6 Jul 2017 International Journal of Hematologic Oncology
The bone marrow transplant clinical nurse specialist in hemato-oncology: an interview with Susan Paskar
23 May 2017 International Journal of Hematologic Oncology
Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco
1 May 2017 International Journal of Hematologic Oncology
Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?
17 Apr 2017 International Journal of Hematologic Oncology
Management of multiple myeloma: the impact of ixazomib’s approval in Canada
1 Feb 2017 International Journal of Hematologic Oncology
Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient

Must watch

13 Feb 2019 Lung
Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Stay up to date

Upcoming event

ESMO Breast Cancer 2019 – annual congress

May 2, 2019 – May 4, 2019

Berlin, Germany

View all

Upcoming event

American Society of Clinical Oncology (ASCO) annual meeting

May 31, 2019 – June 4, 2019

IL, USA

View all

Tweets

Cancer Research UK@CR_UK·

Today is International Clinical Trials Day! In the thread below, we’re exploring the work that goes into clinical trials, through the eyes of our researchers and research nurses. 👇🔬 #ICTD2019

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Management of older adults with acute lymphoblastic leukemia: challenges & current approaches

In Focus: Blood cancer

The bone marrow transplant clinical nurse specialist in hemato-oncology: an interview with Susan Paskar

Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco

Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?

Management of multiple myeloma: the impact of ixazomib’s approval in Canada

Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia

Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Update on recurrent genetic aberrations in acute myeloid leukemia

Current and future immunotherapeutic approaches to multiple myeloma therapy

Management of chronic lymphocytic leukemia in elderly patients

Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors?

Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia

Treating rare lymphoproliferative malignancies: a focus on indolent large granular lymphocytic leukemia

Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study

Promising new strategies to target gene regulatory factors in T-cell acute lymphoblastic leukemia

Novel conditioning regimens for Hodgkin’s and non-Hodgkin’s lymphoma

Mast cell leukemia: a review

T-cell immune suppression in patients with hematologic malignancies: clinical implications

Past, present and future treatment strategies in peripheral T-cell lymphomas

Waldenström macroglobulinemia at 70

Use of signaling pathways as therapeutic targets for blood cancer

Login

International Journal of Hematologic Oncology

Must read

Management of older adults with acute lymphoblastic leukemia: challenges & current approaches

In Focus: Blood cancer

The bone marrow transplant clinical nurse specialist in hemato-oncology: an interview with Susan Paskar

Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco

Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?

Management of multiple myeloma: the impact of ixazomib’s approval in Canada

Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient

Must watch

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Emerging treatment options for pancreatic cancer with Thomas Seufferlein

Tamoxifen, SERMs and sustainable medicine

Seven challenges in immuno-oncology

The importance of a multidisciplinary team in the care of head and neck cancer

Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia

Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Update on recurrent genetic aberrations in acute myeloid leukemia

Current and future immunotherapeutic approaches to multiple myeloma therapy

Management of chronic lymphocytic leukemia in elderly patients

Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors?

Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia

Treating rare lymphoproliferative malignancies: a focus on indolent large granular lymphocytic leukemia

Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study

Promising new strategies to target gene regulatory factors in T-cell acute lymphoblastic leukemia

Novel conditioning regimens for Hodgkin’s and non-Hodgkin’s lymphoma

Mast cell leukemia: a review

T-cell immune suppression in patients with hematologic malignancies: clinical implications

Past, present and future treatment strategies in peripheral T-cell lymphomas

Waldenström macroglobulinemia at 70

Use of signaling pathways as therapeutic targets for blood cancer

Stay up to date

Oncology Central Newsletter